Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In aTyr (ATYR) To Contact Him Directly To Discuss Their Options If you purchased or acquired aTyr common stock between January 16, 2025, and September 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bra ...

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR). Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/atyr-pharma-inc-loss-submission-form/?id=171674&from=3 CLASS PERIOD: January 16, ...

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material informat ...

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired aTyr securiti ...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds ...

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. SO WHAT: If you purchased aTyr Pharma common stock du ...

公司事件概述 - 生物技术公司aTyr Pharma因涉嫌在2025年1月16日至2025年9月12日期间就其主要候选药物Efzofitimod的疗效误导投资者而面临集体诉讼 [1] - 诉讼指控公司高管在隐瞒药物允许患者完全停止使用类固醇的能力的同时，仍对研究设计中的强制递减方法表示信心 [2] - 公司于2025年9月15日宣布，针对肺结节病的EFZO-FIT三期研究未达到其主要终点，即第48周时平均每日口服糖皮质激素剂量相对于基线的变化 [3] 药物临床试验结果 - aTyr Pharma的主要候选药物Efzofitimod在三期临床试验中未能达到主要疗效终点 [3] - 该研究是一项针对肺结节病患者的三期、随机、双盲、安慰剂对照研究，旨在评估静脉注射Efzofitimod的安全性和有效性 [2] - 鉴于令人失望的顶线结果，公司的下一步计划是与美国食品药品监督管理局进行沟通以确定前进路径 [3] 市场反应 - 在宣布三期临床试验失败后，aTyr Pharma普通股股价从2025年9月12日的每股6.03美元收盘价暴跌至2025年9月15日的每股1.02美元 [3] - 此次股价下跌幅度为83.2%，发生在单一交易日内 [3]

公司法律事件 - aTyr Pharma公司因违反证券法而被起诉 [1]

LOS ANGELES--(BUSINESS WIRE)---- $ATYR--ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm. ...

集体诉讼案件基本信息 - Rosen Law Firm代表在2025年1月16日至2025年9月12日期间购买aTyr Pharma普通股的投资者提起集体诉讼 [1] - 投资者若希望作为首席原告，必须在2025年12月8日前向法院提出动议 [1][3] - 投资者可能有权通过风险代理收费安排获得补偿，无需支付任何自付费用 [2] 诉讼案件核心指控 - 指控被告向投资者提供了极其积极的陈述，但同时散布了虚假和误导性陈述，和/或隐瞒了有关Efzofitimod疗效的重大不利事实 [5] - 被隐瞒的关键事实涉及该药物使患者能够完全停止使用类固醇的能力 [5] - 诉讼声称，当真实情况进入市场后，投资者遭受了损失 [5] 律所背景与联系信息 - Rosen Law Firm专注于证券集体诉讼和股东衍生诉讼，在全球代表投资者 [4] - 该律所在2017年被ISS Securities Class Action Services评为证券集体诉讼和解数量第一，自2013年以来每年排名前四 [4] - 该律所为投资者追回数亿美元，仅在2019年就为投资者确保了超过4.38亿美元 [4] - 提供多种联系渠道以加入集体诉讼，包括网站、电话和电子邮件 [3][6][8]